The goal of this clinical trial is to assess the clinical efficacy and safety of sodium aescinate in treating low back pain (LBP) in adult participants.
Meets the diagnostic criteria for chronic low back pain (cLBP) recommended by the Clinical Practice Guidelines for Chronic Low Back Pain in China (2024 Edition): the course of disease lasts at least 12 weeks, with pain occurring in the region below the lower costal margin, above the gluteal crease (horizontal gluteal fold), and between the midaxillary lines on both sides, which may be accompanied by pain in one or both lower extremities.
Has moderate to severe pain, with a Visual Analog Scale (VAS) score > 4 points.
Aged between 18 and 65 years old.
Has a clear understanding of the study content, good compliance, and high willingness to cooperate.
Is in the acute pain phase or acute exacerbation of chronic pain.
Has low back pain caused by other reasons such as infectious diseases or tumors, including but not limited to spinal tumors, spinal tuberculosis, spinal cord infections, etc.
Has a history of allergy to sodium aescinate.
Suffers from systemic diseases or organ dysfunction.